A086890 Stock Overview
A biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ISU Abxis Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,965.00 |
| 52 Week High | ₩8,000.00 |
| 52 Week Low | ₩4,895.00 |
| Beta | 0.71 |
| 11 Month Change | -21.44% |
| 3 Month Change | -23.73% |
| 1 Year Change | -15.56% |
| 33 Year Change | -50.25% |
| 5 Year Change | -19.92% |
| Change since IPO | -46.03% |
Recent News & Updates
Why Investors Shouldn't Be Surprised By ISU Abxis Co., Ltd.'s (KOSDAQ:086890) 26% Share Price Plunge
Nov 14
ISU Abxis (KOSDAQ:086890) Takes On Some Risk With Its Use Of Debt
Nov 12ISU Abxis Co., Ltd.'s (KOSDAQ:086890) Intrinsic Value Is Potentially 84% Above Its Share Price
Aug 07ISU Abxis (KOSDAQ:086890) Takes On Some Risk With Its Use Of Debt
Jun 10Recent updates
Why Investors Shouldn't Be Surprised By ISU Abxis Co., Ltd.'s (KOSDAQ:086890) 26% Share Price Plunge
Nov 14ISU Abxis (KOSDAQ:086890) Takes On Some Risk With Its Use Of Debt
Nov 12ISU Abxis Co., Ltd.'s (KOSDAQ:086890) Intrinsic Value Is Potentially 84% Above Its Share Price
Aug 07ISU Abxis (KOSDAQ:086890) Takes On Some Risk With Its Use Of Debt
Jun 10Benign Growth For ISU Abxis Co., Ltd. (KOSDAQ:086890) Underpins Its Share Price
Mar 12We Think ISU Abxis (KOSDAQ:086890) Has A Fair Chunk Of Debt
Feb 17
ISU Abxis'(KOSDAQ:086890) Share Price Is Down 21% Over The Past Three Years.
Dec 25Shareholder Returns
| A086890 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -3.8% | -4.2% | 1.9% |
| 1Y | -15.6% | 19.5% | -2.6% |
Return vs Industry: A086890 underperformed the KR Biotechs industry which returned 19.5% over the past year.
Return vs Market: A086890 underperformed the KR Market which returned -2.6% over the past year.
Price Volatility
| A086890 volatility | |
|---|---|
| A086890 Average Weekly Movement | 4.6% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A086890 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A086890's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Yeob Hwang | www.abxis.com |
ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; Clotinab, an abciximab that is used as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications; Febulein, a sodium phenylbutyrate granule for the treatment of urea dystrophy; and Trientop, a trientine hydrochloride capsule for the treatment of Wilson’s disease. It develops ISU104 for head, neck, colorectal, and breast cancer; ISU104 CAR-NK for leukemia and solid tumors; ABX2001 for solid tumors; ISU304 for hemophilia B; ISU305 for paroxysmal nocturnal hemoglobinuria and other autoimmune diseases; and ISU203 for dementia caused by Alzheimer’s disease.
ISU Abxis Co., Ltd. Fundamentals Summary
| A086890 fundamental statistics | |
|---|---|
| Market cap | ₩178.43b |
| Earnings (TTM) | -₩5.97b |
| Revenue (TTM) | ₩62.05b |
2.9x
P/S Ratio-29.9x
P/E RatioIs A086890 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A086890 income statement (TTM) | |
|---|---|
| Revenue | ₩62.05b |
| Cost of Revenue | ₩17.52b |
| Gross Profit | ₩44.53b |
| Other Expenses | ₩50.50b |
| Earnings | -₩5.97b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -166.28 |
| Gross Margin | 71.76% |
| Net Profit Margin | -9.62% |
| Debt/Equity Ratio | 38.3% |
How did A086890 perform over the long term?
See historical performance and comparison